Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Piperine, the active compound in black pepper (Piper nigrum), has been investigated for its potential benefits in metabolic syndrome, a cluster of conditions that increase the risk for heart disease, stroke, and type 2 diabetes. Preclinical studies, primarily in animal models and in vitro, suggest that piperine may improve insulin sensitivity, reduce blood glucose levels, and ameliorate lipid profiles. These effects are proposed to be mediated through modulation of adipogenesis, enhancement of antioxidant status, and anti-inflammatory activity. For instance, several studies in rodents have demonstrated that piperine supplementation can decrease fasting blood glucose, triglycerides, and cholesterol, while improving insulin signaling pathways.

However, high-quality clinical evidence in humans is limited. Only a few small clinical trials have evaluated piperine (often in combination with other compounds) for metabolic health parameters, with mixed and sometimes inconclusive results. No major clinical guidelines recognize piperine as a treatment for metabolic syndrome. The existing evidence is promising but preliminary; thus, while there is scientific interest and some early supportive data, robust human research is lacking. Therefore, the evidence rating is moderate to low (2/5), and piperine should not be considered a primary therapy for metabolic syndrome at this time.

More about Piperin
More about Metabolic Syndrome

Other ingredients used for Metabolic Syndrome

Other health conditions supported by Piperin

Products containing Piperin